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Abstract
Oxidative stress is a pathophysiological mechanism potentially involved in psychiatric disor-
ders. The objective of this study was to assess the relationship between total antioxidant
status (TAS) and the functional status of patients with a first episode of psychosis at the
onset of the disease. For this purpose, a sample of 70 patients aged between 9 and 17
years with a first episode of psychosis were followed up for a period of two years. Blood
samples were drawn to measure TAS levels at three time points: at baseline, at one year,
and at two years. Clinical symptoms and functioning were also assessed at the same time
points using various scales. Linear regression analysis was performed to investigate the
relationship between TAS and clinical status at each assessment, adjusting for potential
confounding factors. The distribution of clinical variables was grouped in different percen-
tiles to assess the dose-response in the relation between clinical variables and TAS. At
baseline, patient’s score on Children’s Global Assessment Scale (CGAS) was directly and
significantly associated with TAS with a monotonic increase in percentiles, and surprising
this association was reversed after one and two years of follow-up with a monotonic
decrease. In summary at the onset of the illness, TAS is positively related to clinical status,
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whereas as the illness progresses this correlation is reversed and becomes negative. This
may be the result of an adaptive response.
Introduction
Oxidative stress is a pathophysiological mechanism potentially involved in schizophrenia [1–
5]. There is evidence that patients who have experienced just a single episode of psychosis have
increased levels of lipid peroxidation [6–9] and a decreased total antioxidant capacity [10].
The total antioxidant activity of extracellular fluid can be calculated by adding endogenous
and food-derived antioxidants. Total antioxidant status (TAS) is considered to have great
potential in the search for biomarkers of functional damage in psychiatric disorders, given its
association with the pathophysiology of schizophrenia spectrum disorders [1–3].
A number of case-control studies have been conducted to assess TAS using a cross-sectional
method [10–13]. However, very few studies have explored the relation between TAS and the
functionality of patients over time, with inconsistent results [12,14–16]. In addition, there are
no published data on TAS at the onset of psychotic illness.
The objective of our study was to assess the relationship between total antioxidant status
(TAS) and the functional status of patients with a first episode of psychosis (FEP), at the early
course of the disease. We hypothesized that antioxidant status would be associated with both,
the short and long-term functioning and clinical outcome in these patients.
Materials and methods
Study population
The child and adolescent first-episode psychosis study (CAFEPS) is a cohort study that included
110 patients with FEP aged between nine and 17 years at first assessment. FEP was defined as
the presence of positive psychotic symptoms of delusions or hallucinations for a period of less
than six months. The exclusion criteria for the patients were: presence of a concomitant Axis I
disorder at the time of evaluation that might account for the psychotic symptoms (such as sub-
stance abuse, autistic spectrum disorders, post-traumatic stress disorder, or acute stress disor-
der), mental retardation (MR) per the DSM-IV criteria, including not only an IQ below 70 but
also impaired functioning, pervasive developmental disorder, neurological disorders, history of
head trauma with loss of consciousness, and pregnancy. Occasional substance use was not an
exclusion criterion if positive symptoms persisted for more than 2 weeks after a negative urine
drug test. Information about the sample and protocol has been described in detail elsewhere
[17]. The study was approved by the Clinical Research Ethics Committee of all participating
hospitals: Ethics and Clinical Research Boards of Gregorio Maraño´n General University Hospi-
tal, Clinical Research Ethics Committee of the Hospital Clı´nic de Barcelona, Clinical Research
Ethics Committee of Euskadi, Clinical Research Ethics Committee of University of Navarra
Clinic, Bioethics Committee of the Marque´s de Valdecilla University Hospital and the Clinical
Research Ethics Committee of Niño Jesu´s University Children’s Hospital. Parents or legal
guardians gave written informed consent and patients consented to participate in the study.
Study design and clinical assessments
We conducted a prospective two-year follow-up study to assess the TAS and clinical status of
FEP patients at three time points (at baseline and at one and two years). Clinical assessment
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was performed by trained clinicians who used the following scales: 1) the Spanish version of
the Positive and Negative Syndrome Scale (PANSS)[18], which measures the severity of these
types of symptoms; 2) the Hamilton Rating Scale for Depression (HRSD) [19], which measures
the severity of depressive symptoms; 3) the Young Mania Rating Scale (YMRS), which mea-
sures the severity of manic symptoms [20]; and 4) the Children’s Global Assessment Scale
(CGAS) [21], which rates a patient’s level of functioning and severity of symptoms on a scale
of 0 to 100.
Assessment of TAS
Total antioxidant capacity was assessed by measuring TAS in peripheral blood at the afore-
mentioned three time points. Blood samples (10ml) were collected in heparin-containing
tubes after enrolment between 8:00 and 10:00 AM and were immediately processed as follows:
tubes were centrifuged for 5 min at 400 g at 4˚C. Plasma was collected and centrifuged for 15
min at 14,000 g at 4˚C and then stored at -80˚C until analysis. All samples were analyzed in a
single batch. Baseline data has been published previously by Mico´ et al. [10]. For the present
study, we only used baseline data from the subset of patients who were followed up. TAS was
determined by standardized spectrophotometric assays (Bioxytech) in plasma. Briefly, the TAS
assay relies on the ability of antioxidants present in plasma to inhibit the oxidation of ABTS
(2,2’-azino-bis(3-ethylbenzthiazoline-6-sulphonicacid)), which is monitored by reading absor-
bance at 600 nm [22].
Statistical analysis
After confirming the normality of sociodemographic and clinical data, a descriptive analysis
was performed using means, standard deviation, and percentages. Analysis of variance
(ANOVA) with repeated measures (measuring within subject variables) were used to analyse
the main effect of time on TAS level, clinical parameters and antipsychotic dose. To investigate
if some of the potential confounding factors (age, sex, ethnic group, diagnostic group, parental
level of education, socioeconomic level, living arrangements, use of toxic substances and dose
of medication in chlorpromazine equivalent unit) had influence on TAS levels in each visit,
different statistical models were employed: T-student model for independent samples with cat-
egorical variables of two groups, analysis of variance (ANOVA) for categorical variables of
more than two groups and bivariate Pearson correlation to compare continuous variables. To
evaluate the relationship between TAS and clinical variables, linear regressions were per-
formed and adjusted for the potentially confounding variables that revealed significant in the
previous step. The final models contained (significant) confounding variables and the interac-
tion of independent variables with these confounding variables was also included. To evaluate
the relationship between TAS and scores on clinical scales, differential variables between base-
line and 1-year/2-year values were calculated and linear regressions were performed. In addi-
tion, we used longitudinal linear models to analyse the relationship between the evolution of
TAS and changes in clinical scale scores. These models were created in two steps: 1) we ana-
lysed the influence of the potential confounding variables on the evolution of TAS; 2) we
defined the final models by including the variables that revealed significant in the first step and
the clinical scales. Data are presented in terms of beta coefficients with p values and the corre-
sponding 95% confidence intervals. The distribution of clinical variables was grouped in differ-
ent percentiles to assess dose-response in the relation between clinical variables and TAS. All
statistical analyses were carried out using SPSS v23.0 statistical software, with the significance
level set at p<0.05.
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Results
Characteristics of the sample
Of the 110 patients initially included in the study, 70 were selected to compose the final sam-
ple, as they had attended the baseline visit and at least the first follow-up visit. At the end of the
study, there was a 35% reduction in the size of the sample with respect to the sample of the first
follow-up year. The characteristics of the entire sample are detailed in Table 1. No significant
changes were found in antipsychotic dose over time (F = 1.22; p>0.05). The scores obtained
on the various scales are summarised in Table 2, which shows that scores had improved signifi-
cantly on all scales at the end of the study (p<0.01).
Relationship between oxidative stress and clinical assessment
Comparison of TAS among assessments. TAS improved progressively over the two
years of follow-up, although none of the differences observed among the values measured at
the three time points reached significance (Table 1). None of the potential confounding factors
had a significant influence on TAS levels (S1 Table).
Table 1. Sociodemographic characteristics and total antioxidant status (TAS).
Sociodemographic characteristics Patients (N = 70)
Age in years, n (SD) 15.70 (1.63)
Sex (M/F), mean (%) 50 (71.4)/20(28.6)
Drug use, n baseline (%)
Tobacco 20 (28.6)
Cannabis 20 (28.6)
Alcohol 17 (24.3)
Socioeconomic status, n (%)
5 (lowest) 14 (20.0)
4 23 (32.9)
3 18 (25.7)
2 6 (8.6)
1 (highest) 9 (12.9)
Type of living arrangement, n (%)
Birth parents 64 (91.4)
Alone 1 (1.4)
Other 5 (7.2)
Ethnic group, n (%)
Caucasian 64 (91.4)
Hispanic 4 (5.7)
Other 2 (2.9)
Antipsychotic dose (chlorpromazine equivalent units), mean (SD)
Baseline 260.66 (170.76)
1 year 267,99 (234,77)
2 years 213,42 (133,11)
Variables related to oxidative stress
TAS (mM), mean (SD)
Baseline 0.95 (0.30)
1 year 0.99 (0.42)
2 years 1.14 (0.36)
https://doi.org/10.1371/journal.pone.0194685.t001
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Relationship between TAS and clinical variables. None of the variables included in the
linear regression model as potential confounding factors were significant; hence, only clinical
variables were included in the final model. At baseline, there was a significant positive relation-
ship between TAS and CGAS scores. In contrast, at one year, this association was reversed,
and TAS and YMRS and positive PANSS scores were observed to be all positively related. At
two-year follow-up, TAS was significantly negatively correlated to CGAS scores and positively
associated with YMRS, positive PANSS, negative PANSS, general PANSS and total PANSS
scores (Table 3; Fig 1; S1 and S2 Figs). No correlation based on differential variables was
observed between changes in TAS and variations in clinical scale scores. However, longitudi-
nal linear models confirmed the previous observation of a relationship between TAS and
CGAS (β = -0.006, p = 0.004, 95% CI: (-0.010, -0.002)), PANSS pos (β = 0.013, p = 0.040, 95%
CI: (0.001, 0.025)) and YMRS scales (β = 0.014, p = 0.007, 95% CI: (0.004, 0.025)) after adjust-
ing for gender. When CGAS were distributed in percentiles to analyse dose-response in this
relation, a monotonic increase of the TAS was observed, with higher CGAS at baseline. In con-
trast, at one and two year follow-up, this monotonic effect was also significant, with a negative
relationship between TAS values and CGAS (Table 4).
Discussion
To our knowledge, this is the first study to investigate the relationship between the antioxidant
defence system and clinical and functional status in a sample of adolescents with FEP over
Table 2. Scores in the clinical assessments at the three time points.
Clinical assessment
Baseline 1 year 2 years
PANSS Pos, mean (SD) 24.2 (6.16) 12.63 (6.0) 12.11 (5.47)
PANSS Neg, mean (SD) 21.07 (8.83) 16.54 (6.6) 14.69 (6.40)
PANSS Gen, mean (SD) 47.01 (10.77) 29.63 (11.1) 27.46 (8.17)
PANSS Tot, mean (SD) 92.3 (20.41) 58.80 (20.7) 54.27 (17.54)
YMRS, mean (SD) 17.77 (11.46) 4.90 (7.6) 4.04 (5.20)
HDRS, mean (SD) 19.31 (9.26) 5.76 (6.9) 4.88 (3.99)
CGAS, mean (SD) 37.41 (14.22) 63.52(16.9) 67.11(18.13)
p<0.05
p<0.01
Pos (positive), Neg (negative), Gen (General), Tot (total)
https://doi.org/10.1371/journal.pone.0194685.t002
Table 3. Coefficients of linear regression models between clinical assessment and TAS level at each visit point.
Clinical assessment TAS
Baseline 1 year 2 years
PANSS Pos — B = 0.024; p<0.05 B = 0.030; p<0.05
PANSS Neg — — B = 0.025; p<0.05
PANSS Gen — — B = 0.021;p<0.05
PANSS Tot — — B = 0.011; p<0.01
YMRS — B = 0.018; p<0.05 B = 0.027; p = 0.05
HDRS — — —
CGAS B = 0.005; p<0.05 B = -0.011; p<0.01 B = -0.009; p<0.05
Pos (positive), Neg (negative), Gen (General), Tot (total)
https://doi.org/10.1371/journal.pone.0194685.t003
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time. Interestingly, the antioxidant reserve was smaller in the most severe cases at baseline,
and higher in the most severe cases at follow-up, which may be the result of an adaptation of
the antioxidant defence system in the long term. Specifically, we found that patients with the
most severe positive psychotic symptoms and a worse functionality over two-year follow-up,
exhibited higher levels of antioxidants as shown by the results obtained in the longitudinal lin-
ear models. These results are unlikely to be due to chance, as there is a monotonic increase in
TAS levels at baseline with respect to functionality, and a monotonic decrease of TAS levels
with respect to functionality over time (Fig 2).
We found no previous studies analysing these variables in children, and only Zhang et al.
[12] have assessed the association between cognitive impairment and TAS in adult patients
with schizophrenia. The authors observed that these variables were negatively correlated. In
line with this, a previous study by Sa´nchez-Rodrı´guez et al. [15] comparing elderly people
Fig 1. Relationship between total antioxidant status (TAS) and Children’s Global Assessment Scale (CGAS) scores over a two year follow-up.
https://doi.org/10.1371/journal.pone.0194685.g001
Association between the antioxidant defense system and clinical status
PLOS ONE | https://doi.org/10.1371/journal.pone.0194685 April 26, 2018 6 / 10
living in rural and urban areas revealed a significant negative relationship between cognitive
performance and TAS, with those with the most severe cognitive impairment (lowest scores)
having higher TAS.
The classical theory of hormesis suggests that short exposure to a low level of stress triggers
protection mechanisms that help biological systems to recover baseline levels and cope better
with high levels of stress [23]. In other words, it induces a homeostatic effect. This theory is
also supported by some authors who have hypothesised that the greater the damage caused by
oxidative stress in cells, the higher the antioxidant capacity of the organism [12,15,24,25]. At
cellular level, these compensatory mechanisms occur through enzymatic regulation, which
stimulates antioxidant response, thus increasing defence capacity mediated by the nuclear fac-
tor (erythroid-derived 2)-like 2 (Nrf2) [23,26,27]. Some studies have suggested that the activa-
tion of Nrf2 may reduce the susceptibility of neurons, astrocytes, oligodendrocytes and
microglia to oxidative damage, and this is of great importance for potential therapeutic strate-
gies [28,29].
Although it is uncertain that changes in peripheral TAS levels reflect TAS variations in the
central nervous system, the evidence obtained in our study supports the use of peripheral TAS
markers in patients with first-episode psychosis, based on the special sensitivity of the brain to
oxidative damage [30]. In addition, recent studies have revealed that plasma markers correlate
Table 4. Effect size of CGAS on TAS (and 95% CIs).
BASELINE 1 YEAR 2 YEAR
Percentiles CGAS TAS Effect Size (95% CI) CGAS TAS Effect Size
(95% CI)
CGAS TAS Effect Size
(95% CI)
P3 15 0.08 (0.002, 0.148) 35 -0.39 (-0.626, -0.144) 35 -0.32 (-0.573, -0.068)
P25 30 0.15 (0.003, 0.297) 50 -0.55 (-0.894, -0.206) 51 -0.46 (-0.828, -0.092)
P50 40 0.20 (0.004, 0.396) 63 -0.69 (-1.124, -0.256) 70.5 -0.64 (-1.149, -0.131)
P75 45 0.23 (0.010, 0.450) 80 -0.88 (-1.431, -0.329) 85 -0.77 (-1.383, -0.157)
P97 60 0.33 (0.012, 0.648) 95 -1.05 (-1.704, -0.396) 95 -0.86 (-1.545, -0.175)
https://doi.org/10.1371/journal.pone.0194685.t004
Fig 2. Relationship between CGAS score and TAS level at baseline and at two-year follow-up assessment. a) At
baseline, there is a positive significant relationship between CGAS and TAS indicating that the better the patient’s
functioning, the higher his level of TAS; b) at one year and at two years of follow-up, this relationship is significantly
reversed, with patients with the highest levels of TAS having the worst functionality.
https://doi.org/10.1371/journal.pone.0194685.g002
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to cerebrospinal fluid [31]and postmortem brain tissue [32] markers, which is suggestive of a
parallel and synchronized activity between the peripheral and central systems [33].
Our study has several limitations and strengths. A limitation is related to the follow-up of
patients. This being a two-year longitudinal study of children and adolescents, follow-up of all
patients was difficult. On the other hand, the strengths of the study include that the sample
was highly homogeneous in terms of age, duration of the illness, and pharmacological treat-
ment, and that a long-term follow-up was conducted. Further longitudinal studies should be
performed in the future to determine the antioxidant status of patients with FEP and its poten-
tial relationship with the transcription factor Nrf2; this would allow to investigate the patho-
physiology of this condition and identify new pharmacological targets.
Conclusions
In brief, our data indicates that, in the early stages of the illness, FEP patients with a poorer
clinical status have a lower antioxidant capacity but in the long term, this correlation is
reversed and their antioxidant defence capacity seems to improve as a compensatory response
mechanism of the body. This finding should be seriously considered, as it suggests that the
antioxidant treatments currently under study should be only applied during the early stages of
the illness or, at least, their long-term use is more questionable.
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